Vaccinex (NASDAQ:VCNX) Stock Price Down 16.4% – Here’s What Happened

Vaccinex, Inc. (NASDAQ:VCNX)’s stock price traded down 16.4% during mid-day trading on Tuesday . The company traded as low as $0.80 and last traded at $0.8357. 1,348 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 3,696 shares. The stock had previously closed at $1.00.

Vaccinex Stock Down 16.4%

The stock has a market capitalization of $2.17 million, a PE ratio of -0.02 and a beta of 1.10. The stock has a fifty day moving average of $1.02 and a 200-day moving average of $0.98.

About Vaccinex

Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.

In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.